Eisai Submits SBLA To FDA For Traditional Approval Of Leqembi For Alzheimer's Disease Treatment
7/1 05:52
(RTTNews) - Eisai has submitted a supplemental biologics license application to the U.S. Food and Drug Administration for traditional approval of leqembi (lecanemab-irmb) for the treatment of alzheimer's disease, Eisai Co., Ltd. and Biogen Inc. (BIIB) said in a statement on Frida...